The novel time‐limited combinations with the bcl‐2 inhibitor venetoclax can induce deep responses even in CLL cases with unusual and biologically aggressive presentations, like the skin masses of our patient. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.